Michael Mcfadden, a Senior Officer, acquired 220,166 Common Shares on an indirect ownership basis for registered holder Michael and Sherri Mcfadden Family Trust at a price of $1.500 through a prospectus or prospectus exempt offering on October 1st, 2021. This represents a $715,540 investment into the company's shares and an account share holdings change of greater than 100%.
Alpha Cognition Inc. is a clinical stage, biopharmaceutical company
dedicated to developing treatments for under-served neurodegenerative
diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis
(ALS).
No Comments